Search
binimetinib
FDA approved June 2018
Indications:
- for use in combination with encorafenib for the treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma
Dosage:
- 15 mg PO
Tablets: 15 mg tablets
Mechanism of action:
- selective inhibitor of MEK
General
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=10288191
References
- RxNorm
- Wikipedia: Binimetinib
https://en.wikipedia.org/wiki/Binimetinib
Component-of
binimetinib/encorafenib